Example of sample data. by Xiying Wang (4859998)

“…In contrast, the EGA-BPNN model achieves a significantly lower mean absolute relative error of 0.41% for single-flow prediction, demonstrating superior prediction performance. …”

Structure of BPNN. by Xiying Wang (4859998)

“…In contrast, the EGA-BPNN model achieves a significantly lower mean absolute relative error of 0.41% for single-flow prediction, demonstrating superior prediction performance. …”

The workflow of EGA-BPNN. by Xiying Wang (4859998)

“…In contrast, the EGA-BPNN model achieves a significantly lower mean absolute relative error of 0.41% for single-flow prediction, demonstrating superior prediction performance. …”

S1 Data - by Xiying Wang (4859998)

“…In contrast, the EGA-BPNN model achieves a significantly lower mean absolute relative error of 0.41% for single-flow prediction, demonstrating superior prediction performance. …”

Algorithm flow of the GA-BPNN model. by Xiying Wang (4859998)

“…In contrast, the EGA-BPNN model achieves a significantly lower mean absolute relative error of 0.41% for single-flow prediction, demonstrating superior prediction performance. …”

Highest posterior density (HPD) of the posterior genotypic main effects (A), probability of superior performance across environments (B), and probability of superior stability acro... by Mohammadreza Shiri (10368554)

CONSORT diagram. by Aina Gabarrell-Pascuet (17696594)

“…Statistically significant (<i>p</i><0.01) decreases in emotional loneliness and depressive symptoms were observed following the intervention. …”

Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs. by Aga E. Gelgie (17661720)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Subjects:

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects: